Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Biochem Behav ; 58(3): 695-9, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9329061

ABSTRACT

A rodent model of nicotine dependence has been developed based on continuous subcutaneous (s.c.) infusion of nicotine tartrate. Nicotine abstinence syndrome was precipitated by s.c. injection of the nicotinic antagonist mecamylamine, which freely crosses the blood-brain barrier. In contrast, the nicotinic antagonist hexamethonium crosses the blood-brain barrier very poorly. This study determined whether central or peripheral administration of hexamethonium could precipitate nicotine abstinence. In the first experiment, 26 nicotine-dependent rats were injected s.c. with 0.5, 5 or 10 mg/kg hexamethonium dichloride or saline alone and observed for 20 min. Few abstinence signs were observed in any group; there was no significant drug effect. In the second experiment, 18 rats were cannulated in the third ventricle and rendered nicotine dependent. One week later, rats were injected through the cannula with 12 or 18 ng hexamethonium or saline alone and observed for 20 min. Both dose groups differed significantly from the saline-injected group, and there was a significant positive linear trend of signs as a function of dose. The high dose had no significant effect in 14 nondependent rats. We conclude that hexamethonium is much more potent by the central route, and there is a major central nervous system component in nicotine dependence.


Subject(s)
Central Nervous System/physiology , Hexamethonium/pharmacology , Nicotine/adverse effects , Nicotinic Antagonists/pharmacology , Peripheral Nervous System/physiology , Substance Withdrawal Syndrome/psychology , Animals , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Hexamethonium/administration & dosage , Injections, Intraventricular , Injections, Subcutaneous , Male , Nicotinic Antagonists/administration & dosage , Rats , Rats, Sprague-Dawley
2.
Pharmacol Biochem Behav ; 54(3): 581-5, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8743632

ABSTRACT

In a recently introduced rodent model of nicotine abstinence syndrome the observed behavioral signs closely resembled those typical of rat opiate abstinence syndrome. Nicotine-induced release of endogenous opioids may contribute to nicotine dependence; morphine potently reverses nicotine abstinence signs, while naloxone precipitates abstinence signs and prevents nicotine from alleviating them. Considerable evidence suggests that neuropeptide FF, an endogenous antiopiate peptide, contributes to opiate dependence. Third ventricle injection of neuropeptide FF precipitates abstinence syndrome in morphine-dependent rats, as does SC injection of its lipophilic analogs, dansyl-PQRFamide and dansyl-RFamide. Might NPFF also play a role in nicotine dependence? In the present study, SC injection of 15 or 25 mg/kg dansyl-RFamide or vehicle alone dose dependently precipitated an abstinence syndrome in nicotine-dependent rats. There was a significant, p < 0.01, positive linear trend of abstinence signs as a function of dose. Categories of abstinence signs had the same rank ordering by frequency as observed in spontaneous nicotine abstinence. Injection of 25 mg/kg dansyl-RFamide SC had no significant effect in nondependent rats.


Subject(s)
Narcotic Antagonists/pharmacology , Nicotine/adverse effects , Nicotinic Agonists/adverse effects , Oligopeptides/pharmacology , Substance Withdrawal Syndrome/psychology , Amino Acid Sequence , Animals , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Injections, Subcutaneous , Male , Molecular Sequence Data , Neuropeptides/administration & dosage , Neuropeptides/pharmacology , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...